Enzo Life Sciences
ActiveSummary
The computed 12-month bankruptcy probability of Enzo Life Sciences is 3.2% (moderate). The 2025 annual accounts show negative equity (-€1.0m) and a net result of -€185,783. Equity is shrinking by about 21% per year across the filed financial years. Its solvency ranks better than 5% of 6,139 sector peers (NACE 46, financial year 2025). The company has been active since 1996 and the Belgian Official Gazette contains no insolvency or warning signals.
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- Enzo Life Sciences
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Brussels Gewest” (deed in Dutch)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- “15 te De gekozen bestuurders aanvaarden hun mandaat en verklaren dat er geen maatregel bestaat die zich verzet tegen hun benoeming. Het…”deed of 10-11-2025
- Board ruleHow the board is made up, meets and takes decisions.
- “Een of meer bestuurders,natuurlijke personen of rechtspersonen,al dan niet aandeelhouder,met of zonder beperking van duur,statutair…” (deed in Dutch)“Voeren gezamenlijk bestuur, voert alleen bestuur” (deed in Dutch)2 more provisions on this in the deeddeed of 20-12-2023
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- One provision in the deed
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Alle machten in WVV zonder bijzondere machtiging;algemene vergadering kan te allen tijde beperken bij gewone meerderheid, desgevallend een…” (deed in Dutch)